References
- Ai J, Gao H, He SZ, Wang L, Luo DL, Yang BF (2001): Effects of matrine, artemisinin, and tetrandrine on cytosolic [Ca2+]i in guinea pig ventricular myocytes. Acta Pharmacol Sin 22: 512–515. [PUBMED], [INFOTRIEVE], [CSA]
- Clark SS, McLaughlin J, Timmonis M, Pendergast AM, Ben-Neriah Y, Dow L, Rovera G, Smith SD, Witte ON (1988): Expression of a distinctive bcr-abl oncogene in Ph1-positive acute lymphoblastic leukemia (ALL). Science 239: 775–777. [PUBMED], [INFOTRIEVE], [CSA]
- Cortes JE, Talpaz M, Beran M, O'Brien SM, Rios MB, Stass S, Kantarjian HM (1995): Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer 75: 464–470. [PUBMED], [INFOTRIEVE], [CSA]
- Cortez D, Reuther G, Pendergast AM (1997): The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene 15: 2333–2342. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Daley G, Ven Etten R, Baltimore D (1990): Induction of chronic myelogenous leukemia in mice by the p210bcr/abl gene of the Philadelphia chromosome. Science 247: 824–830. [PUBMED], [INFOTRIEVE], [CSA]
- Dhut S, Champlin T, Young BD (1990): BCR/ABL and ABL proteins: Biochemical characterization and localization. Leukemia 4: 745–750. [PUBMED], [INFOTRIEVE], [CSA]
- Ding T, Wang WR, Zhang GY, Cheng MZ, Li SH (2002): The preparing and clinical applications of complex matrine liniment. ACTA Chinese Medicine and Pharmacology (Chinese) 30: 47–48. [CSA]
- Dorsey JF, Jove R, Kraker AJ, Wu J (2000): The pyrido[2,3-d.]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res 60: 3127–3131. [PUBMED], [INFOTRIEVE], [CSA]
- Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001): Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038–1042. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB (1996): Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 2: 561–566. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fang GF, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, Bhalla KN (2000): CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 96: 2246–2253. [PUBMED], [INFOTRIEVE], [CSA]
- Feng JL, Huang GS, Zhang YQ, Wang Z, Zhang XH, Guo Y, Yan GQ (2003): Matrine effects on JM cells by inhibiting proliferation and inducing apoptosis. China J Chinese Met Med (Chinese) 28: 437–442. [CSA]
- Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL (2001): Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876–880. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Heisterkamp N, Jenster G, ten Hoeve J, Zovich D, Pattengale PK, Groffen J (1990): Acute leukaemia in bcr/abl transgenic mice. Nature 344: 251–253. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P (2003): Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation towards the erythroid lineage. FASEB J 17: 2160–2162. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B, Goldman J, O'Brien SG, Russell N, Fischer T, Ottmann O, Cony-Makhoul P, Facon T, Stone R, Miller C, Tallman M, Brown R, Schuster M, Loughran T, Gratwohl A, Mandelli F, Saglio G, Lazzarino M, Russo D, Baccarani M, Morra E (2002): Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. J Engl J Med 346: 645–652. [CSA], [CROSSREF]
- Laneuville P, Heisterkamp N, Groffen J (1991): Expression of the chronic myelogenous leukemia-associated p21obcr/abl oncoprotein in a murine IL-3 dependent myeloid cell line. Oncogene 6: 275–282. [PUBMED], [INFOTRIEVE], [CSA]
- Li Y, He LR (2000): Pharmacological study of Sophora. alkaloid actions on the cardiovascular system. Chinese Trad Herbal drugs (Chinese) 31: 227–229. [CSA]
- Liu J, Zhu M, Shi R, Yang M (2003): Radix Sophorae flavescentis for chronic hepatitis B: A systematic review of randomized trials. AM J Chin Med 31: 337–354. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Long Y, Lin XT, Zeng KL, Zhang L (2004): Efficacy of intramuscular matrine in the treatment of chronic hepatitis B. Hepatobiliary Pancreat Dis Int 3: 69–72. [PUBMED], [INFOTRIEVE], [CSA]
- Lozzio CB, Lozzio BB (1975): Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 45: 321–334. [PUBMED], [INFOTRIEVE], [CSA]
- Lugo TG, Pendergast AM, Muller AJ, Witte ON (1990): Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science 247: 1079–1082. [PUBMED], [INFOTRIEVE], [CSA]
- Ma HS, H Liu Y, Li C, Chong SY, Shun H, Feng YM, Shu MX (1996): Modulation of malignant phenotype and the immunological response of tumor cell by sophora flavescens Ait.. Chinese J Clin Oncol (Chinese) 23: 799–780. [CSA]
- Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM, Melo JV (2000): Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance. Blood 96: 1070–1079. [PUBMED], [INFOTRIEVE], [CSA]
- Niu KZ (1997): Pharmacology and clinical application of Sophora flavescentis.. Int J Oriental Med 22: 75–81. [CSA]
- Nowell PC, Hungerford DA (1960): A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497–1501. [CSA]
- Puil L, Liu J, Gish G, Mbamalu G, Bowtell D, Pelicci PG, Arlinghaus R, Pawson T (1994): Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway. EMBO J 13: 764–773. [PUBMED], [INFOTRIEVE], [CSA]
- Qin JP, Jiang JK, Zhang Y, Wang XW (1994): Differentiation of Human erythroid leukemia K562 cells induced by Sophora flavescens extracts. J Chongqing Med Univ (Chinese) 2: 150–151. [CSA]
- Richardson JM, Morla AO, Wang JY (1987): Reduction in protein tyrosine phosphorylation during differentiation of human leukemia cell line K-562. Cancer Res 47: 4066–4070. [PUBMED], [INFOTRIEVE], [CSA]
- Rivero JA, Adunyah SE (1996): Sodium butyrate induces tyrosine phosphorylation and activation of MAP kinase (ERK-1) in human K562 cells. Biochem Biophys Res Commun 224: 796–801. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA (2002): Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci USA 99: 10700–10705. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Sattler M, Salgia R (1997): Activation of hematopoietic growth factor signal transduction pathways by the human oncogene BCR/ABL. Cytokine Growth Factor Rev 8: 63–79. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B (1997): Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3K/Akt-dependent pathway. EMBO J 16: 6151–6161. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B, Calabretta B (1995): Phosphatidylinositol-3 kinase activity in regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood 86: 726–736. [PUBMED], [INFOTRIEVE], [CSA]
- Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz Am, Calabretta B (1991): Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253: 562–565. [PUBMED], [INFOTRIEVE], [CSA]
- Tang S, Cai B, Xu H, Li H, Guo S, Yang L, Lu B, Zhang L (2002): The influence of matrine on apoptosis of fibroblasts and the expression of apoptotic modulation related protein in hypertrophic scar of rabbit ear. Chinese J Burns (Chinese) 18: 299–301. [CSA]
- Xu XR, Jiang JK (1998): Recent progress in anticancer bioactivity study of Sophora flavescens. and its alkaloids. Chinese J Integrated Trad Chinese Western Med (Chinese) 4: 235–239. [CSA]
- Zhang YL (1996): Clinical study on matrine for the treatment of psoriasis. Hebei J Med Sci (Chinese) 69: 590–591. [CSA]
- Zhang LP, Jiang JK, Tam JW, Zhang Y, Liu XS, Xu XR, Liu BZ, He YJ (2001): Effects of matrine on proliferation and differentiation in K-562 cells. Leuk Res 25: 793–800. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Zhang BH, Wang NS, Li XJ, Kong XJ, Cai YL (1990): Anti-arrhythmic effects of matrine. Acta Pharmacol Sin 11: 253–257. [CSA]
- Zhang JP, Zhang M, Zhou JP, Liu FT, Zhou B, Xie WF (2001). Antifibrotic effects of matrine on in vitro. and in vivo. models of liver fibrosis in rats Acta Pharmacol Sin 22: 183–186. [PUBMED], [INFOTRIEVE], [CSA]